Evidenze Revenue and Competitors

Madrid, Spain

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Evidenze's estimated annual revenue is currently $31M per year.(i)
  • Evidenze's estimated revenue per employee is $201,000

Employee Data

  • Evidenze has 154 Employees.(i)
  • Evidenze grew their employee count by 7% last year.

Evidenze's People

NameTitleEmail/Phone
1
Project Manager and eHealth ConsultantReveal Email/Phone
2
Técnica de recursos humanosReveal Email/Phone
3
Desarrollo de negocio EVIDENZE medical education & PSPsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.7M985%N/AN/A
#2
$19.7M9842%N/AN/A
#3
$10.5M52-17%N/AN/A
#4
$32.4M16111%N/AN/A
#5
$49M2446%N/AN/A
#6
$7.2M36N/AN/AN/A
#7
$36.8M1839%N/AN/A
#8
$44.8M22313%N/AN/A
#9
$147.9M73610%N/AN/A
#10
$29.3M146-5%N/AN/A
Add Company

What Is Evidenze?

Compañía Internacional de servicios y soluciones en la gestión del conocimiento en salud. Especializada en investigación clínica, formación médica, programas de soporte a pacientes y comunicación.

keywords:N/A

N/A

Total Funding

154

Number of Employees

$31M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Evidenze News

2022-04-20 - Decarbonizzare i trasporti, Giovannini in controtendenza supportata ...

... Giovannini in controtendenza supportata da evidenze scientifiche e ... con sottotitolo “Evidenze scientifiche e proposte di policy”,...

2022-04-20 - Decarbonizzare i trasporti | Giovannini in controtendenza con ...

Decarbonizzare i trasporti | Giovannini in controtendenza con evidenze scientifiche e proposte di policy. di Claudio Quintano* Ieri, venerdì 22...

2022-04-19 - Decarbonizzazione trasporti: Rapporto STEMI, per auto e veicoli ...

Le principali evidenze del Rapporto. Automobili e furgoni commerciali - I veicoli elettrici a batteria (BEV) sono l'opzione più idonea per...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$25.4M1548%N/A
#2
$31M1547%N/A
#3
$54.7M15413%N/A
#4
N/A15450%N/A
#5
$54.2M1555%$175M